PDSB vs. FENC, VOR, INBX, CGC, LIMN, ESPR, BTMD, NBTX, PRQR, and SLRN
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Adherex Technologies (FENC), Vor Biopharma (VOR), Inhibrx Biosciences (INBX), Canopy Growth (CGC), Liminatus Pharma (LIMN), Esperion Therapeutics (ESPR), biote (BTMD), Nanobiotix (NBTX), ProQR Therapeutics (PRQR), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry.
PDS Biotechnology vs. Its Competitors
Adherex Technologies (NASDAQ:FENC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.
Adherex Technologies has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
Adherex Technologies has higher revenue and earnings than PDS Biotechnology. Adherex Technologies is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.
PDS Biotechnology has a net margin of 0.00% compared to Adherex Technologies' net margin of -45.52%. Adherex Technologies' return on equity of 0.00% beat PDS Biotechnology's return on equity.
55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 11.8% of Adherex Technologies shares are held by insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Adherex Technologies presently has a consensus price target of $13.00, suggesting a potential upside of 48.06%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 625.81%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Adherex Technologies.
In the previous week, Adherex Technologies had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 6 mentions for Adherex Technologies and 4 mentions for PDS Biotechnology. Adherex Technologies' average media sentiment score of 0.60 beat PDS Biotechnology's score of 0.18 indicating that Adherex Technologies is being referred to more favorably in the media.
Summary
Adherex Technologies beats PDS Biotechnology on 10 of the 15 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:PDSB) was last updated on 7/12/2025 by MarketBeat.com Staff
